HUP0401753A2 - Antigénprezentáló sejtek, készítésükre szolgáló eljárások és rákvakcinaként történő alkalmazásuk - Google Patents

Antigénprezentáló sejtek, készítésükre szolgáló eljárások és rákvakcinaként történő alkalmazásuk

Info

Publication number
HUP0401753A2
HUP0401753A2 HU0401753A HUP0401753A HUP0401753A2 HU P0401753 A2 HUP0401753 A2 HU P0401753A2 HU 0401753 A HU0401753 A HU 0401753A HU P0401753 A HUP0401753 A HU P0401753A HU P0401753 A2 HUP0401753 A2 HU P0401753A2
Authority
HU
Hungary
Prior art keywords
cells
subject
cancer vaccines
cellular components
preparation
Prior art date
Application number
HU0401753A
Other languages
English (en)
Inventor
Rita Santis
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of HUP0401753A2 publication Critical patent/HUP0401753A2/hu
Publication of HUP0401753A3 publication Critical patent/HUP0401753A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány tárgyát képezi eljárás antigénprezentáló sejtekelőállítására, amely során sejteket gyűjtenek egy alanyból, aktiváljáka sejteket, tenyésztik, és adott esetben ex vivo elszaporítják azaktivált sejteket, és a sejteket DNS-t hipometiláló anyagokkalkezelik, hogy a sejtek egyidejűleg több tumorasszociált antigéntexpresszáljanak. A találmány tárgyát képezik továbbá a találmányszerinti eljárással előállított sejtek, a sejtes komponenseik, és asejtek és/vagy a sejtes komponensek rákvakcinaként történőalkalmazása. A találmány szerinti sejtek és/vagy sejtes komponenseikegy vagy több rákantigént konstitutívan expresszáló, különbözőhisztotípusú malignus betegségek megelőzésére és kezelésérealkalmazhatók. Ó
HU0401753A 2001-07-30 2002-07-25 Antigen presenting cells, method for their preparation and their use for cancer vaccines HUP0401753A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IT2001/000419 WO2003012085A1 (en) 2001-07-30 2001-07-30 Antigen presenting cells, method for their preparation and their use for cancer vaccines
PCT/IT2002/000488 WO2003012086A1 (en) 2001-07-30 2002-07-25 Antigen presenting cells, method for their preparation and their use for cancer vaccines

Publications (2)

Publication Number Publication Date
HUP0401753A2 true HUP0401753A2 (hu) 2004-11-29
HUP0401753A3 HUP0401753A3 (en) 2011-04-28

Family

ID=11133712

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401753A HUP0401753A3 (en) 2001-07-30 2002-07-25 Antigen presenting cells, method for their preparation and their use for cancer vaccines

Country Status (17)

Country Link
US (3) US20030119187A1 (hu)
EP (1) EP1412485B1 (hu)
JP (1) JP2004536615A (hu)
KR (1) KR100916670B1 (hu)
CN (1) CN100591762C (hu)
AT (1) ATE505533T1 (hu)
AU (1) AU2002334387B2 (hu)
BR (1) BR0211520A (hu)
CA (1) CA2453522C (hu)
DE (1) DE60239741D1 (hu)
DK (1) DK1412485T3 (hu)
ES (1) ES2367256T3 (hu)
HK (1) HK1068913A1 (hu)
HU (1) HUP0401753A3 (hu)
MX (1) MXPA04000885A (hu)
PL (1) PL211907B1 (hu)
WO (2) WO2003012085A1 (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
PT1592441E (pt) * 2003-02-06 2012-05-21 Aduro Biotech Listeria atenuada relativamente à entrada em células não patogénicas, vacinas compreendendo a listeria e métodos para sua utilização
EP1592442A2 (en) * 2003-02-06 2005-11-09 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
DE10329240A1 (de) * 2003-06-24 2005-01-20 Epigenomics Ag Verfahren zur Analyse des Cytosin-Methylierungsstatus von Cancer-Testis-Antigenen für eine individualisierte Immuntherapie
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US7619058B2 (en) 2004-01-20 2009-11-17 Aichi Prefecture Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same
WO2005075646A1 (ja) * 2004-02-03 2005-08-18 Kurume University ストレス誘導抗アポトーシス分子（ｉｅｘ−１）由来ペプチド
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2007011693A2 (en) 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
GB0700058D0 (en) * 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
EP2510086A4 (en) * 2009-12-08 2013-05-22 Wolf Wilson Mfg Corp IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES
KR20190107166A (ko) * 2011-07-07 2019-09-18 리서치 캔서 인스티튜트 오브 아메리카 암 치료 시스템, 방법 및 제형
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
MX359314B (es) 2011-08-30 2018-09-25 Astex Pharmaceuticals Inc Star Formulaciones derivadas de decitabina.
DK2914254T3 (en) * 2012-10-30 2020-03-30 Mei Pharma Inc Combination therapies to treat chemoresistant cancers
US9562219B2 (en) 2013-12-27 2017-02-07 SOTIO a.s. Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer
WO2016190940A1 (en) * 2015-05-22 2016-12-01 Czerniecki Brian J Manufacturing multi-dose injection ready dendritic cell vaccines
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
CN105132371B (zh) * 2015-07-24 2016-05-25 北京鼎成肽源生物技术有限公司 体外提呈、激活dc细胞的方法及其应用
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
CN107557333B (zh) * 2017-10-16 2018-07-31 北京鼎成肽源生物技术有限公司 一种用于细胞治疗的新抗原呈递细胞的制备方法
KR102319259B1 (ko) 2019-07-26 2021-10-28 정재웅 지반천공기용 확장리더 안전제어장치
WO2021027057A1 (zh) * 2019-08-15 2021-02-18 成都冕康生物科技有限公司 一种针对ebv病毒抗原的b细胞疫苗及其制备方法
CN114099655A (zh) * 2021-11-16 2022-03-01 苏州大学 一种预防或治疗癌症的疫苗系统及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0817854A2 (en) * 1995-03-31 1998-01-14 Wolf, Hans, Prof. Dr. Antigen presentation system based on retrovirus-like particles
US6420176B1 (en) * 1997-09-15 2002-07-16 Genetic Immunity, Llc. Composition for delivering DNA into antigen presenting cells
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines

Also Published As

Publication number Publication date
PL211907B1 (pl) 2012-07-31
US7883889B2 (en) 2011-02-08
DE60239741D1 (de) 2011-05-26
HUP0401753A3 (en) 2011-04-28
CN100591762C (zh) 2010-02-24
US20040185563A1 (en) 2004-09-23
MXPA04000885A (es) 2004-06-03
JP2004536615A (ja) 2004-12-09
PL367617A1 (en) 2005-03-07
HK1068913A1 (en) 2005-05-06
ES2367256T3 (es) 2011-10-31
KR20040021662A (ko) 2004-03-10
US20050002920A1 (en) 2005-01-06
US20030119187A1 (en) 2003-06-26
EP1412485A1 (en) 2004-04-28
CN1537161A (zh) 2004-10-13
ATE505533T1 (de) 2011-04-15
AU2002334387B2 (en) 2007-10-04
BR0211520A (pt) 2004-09-14
DK1412485T3 (da) 2011-08-01
EP1412485B1 (en) 2011-04-13
WO2003012085A1 (en) 2003-02-13
CA2453522A1 (en) 2003-02-13
CA2453522C (en) 2013-04-30
KR100916670B1 (ko) 2009-09-08
WO2003012086A1 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
HUP0401753A2 (hu) Antigénprezentáló sejtek, készítésükre szolgáló eljárások és rákvakcinaként történő alkalmazásuk
TNSN05300A1 (en) Treatment with anti-vegf antibodies
ATE429442T1 (de) Zusammensetzungen und verfahren zur wt1- spezifischen immuntherapie
HUP0303720A2 (hu) Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény
HUP0402067A2 (hu) Oltóanyagok
HK1083866A1 (en) Hla-a24-restricted cancer antigen peptides hla-a24
NO20015073L (no) Vaksiner
MXPA03001634A (es) Polipeptido tumoral cripto.
WO2004112825A3 (en) Combinations of tumor-associated antigens for the treatment of various types of cancers
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
HUP0203056A1 (hu) Vakcinakészítmény
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
WO2001035989A3 (de) Verwendung von anti-idiotypische antikörpern als impfstoffe gegenkrebs
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
HUP0401519A2 (hu) Autológ T-sejt-vakcinák
WO2004031354A3 (en) Human sarcoma-associated antigens
YU63702A (sh) Novo antitelo sa specifičnošću za rak debelog creva
WO2004106379A8 (en) Immunotherapy of rectal cancer
MY127452A (en) Vaccines.
WO2020186111A3 (en) Vista-binding antibodies and uses thereof
WO2006105343A3 (en) Dkkl-i splice product modulators for cancer diagnosis and therapy
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished